Analysts Set Organon & Co. (NYSE:OGN) Target Price at $8.50

Shares of Organon & Co. (NYSE:OGN) have been given a consensus recommendation of “Reduce” by the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $8.50.

Several equities analysts recently weighed in on OGN shares. Barclays increased their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a report on Tuesday, February 24th. Zacks Research lowered shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Finally, Wall Street Zen cut shares of Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st.

Hedge Funds Weigh In On Organon & Co.

Several hedge funds have recently added to or reduced their stakes in OGN. AQR Capital Management LLC boosted its holdings in Organon & Co. by 105.2% during the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock worth $61,282,000 after buying an additional 4,394,814 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Organon & Co. by 11.3% during the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after buying an additional 3,650,860 shares during the period. Norges Bank bought a new stake in shares of Organon & Co. in the 2nd quarter valued at about $19,778,000. UBS Group AG increased its stake in shares of Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after acquiring an additional 1,527,492 shares during the last quarter. Finally, Private Management Group Inc. raised its position in shares of Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after acquiring an additional 1,204,979 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of NYSE:OGN opened at $5.84 on Friday. The stock has a market capitalization of $1.52 billion, a P/E ratio of 8.23, a P/E/G ratio of 0.54 and a beta of 0.61. Organon & Co. has a 1-year low of $5.76 and a 1-year high of $14.94. The company has a current ratio of 1.82, a quick ratio of 1.23 and a debt-to-equity ratio of 11.47. The business has a 50-day moving average price of $7.47 and a two-hundred day moving average price of $8.01.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The business had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.52 billion. During the same quarter in the previous year, the company posted $0.90 earnings per share. The business’s revenue for the quarter was down 5.3% on a year-over-year basis. Equities analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Monday, February 23rd were paid a dividend of $0.02 per share. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.4%. Organon & Co.’s payout ratio is 11.27%.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.